Trade Heron Therapeutics, Inc. - HRTX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 2.75 |
| Open | 2.77 |
| 1-Year Change | 100.72% |
| Day's Range | 2.77 - 2.89 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| May 10, 2024 | 2.75 | -0.18 | -6.14% | 2.93 | 3.02 | 2.70 |
| May 9, 2024 | 2.91 | -0.09 | -3.00% | 3.00 | 3.02 | 2.82 |
| May 8, 2024 | 2.98 | 0.23 | 8.36% | 2.75 | 3.01 | 2.73 |
| May 7, 2024 | 2.84 | -0.15 | -5.02% | 2.99 | 3.01 | 2.60 |
| May 6, 2024 | 2.82 | 0.21 | 8.05% | 2.61 | 2.83 | 2.59 |
| May 3, 2024 | 2.58 | -0.07 | -2.64% | 2.65 | 2.72 | 2.55 |
| May 2, 2024 | 2.52 | 0.17 | 7.23% | 2.35 | 2.52 | 2.31 |
| May 1, 2024 | 2.31 | 0.00 | 0.00% | 2.31 | 2.46 | 2.30 |
| Apr 30, 2024 | 2.29 | -0.15 | -6.15% | 2.44 | 2.44 | 2.25 |
| Apr 29, 2024 | 2.47 | 0.03 | 1.23% | 2.44 | 2.52 | 2.43 |
| Apr 26, 2024 | 2.43 | -0.18 | -6.90% | 2.61 | 2.61 | 2.43 |
| Apr 25, 2024 | 2.53 | -0.10 | -3.80% | 2.63 | 2.63 | 2.44 |
| Apr 24, 2024 | 2.63 | -0.16 | -5.73% | 2.79 | 2.81 | 2.62 |
| Apr 23, 2024 | 2.77 | 0.09 | 3.36% | 2.68 | 3.12 | 2.65 |
| Apr 22, 2024 | 2.57 | -0.01 | -0.39% | 2.58 | 2.69 | 2.55 |
| Apr 19, 2024 | 2.61 | -0.05 | -1.88% | 2.66 | 2.71 | 2.49 |
| Apr 18, 2024 | 2.69 | -0.03 | -1.10% | 2.72 | 2.93 | 2.67 |
| Apr 17, 2024 | 2.75 | -0.15 | -5.17% | 2.90 | 3.00 | 2.75 |
| Apr 16, 2024 | 2.91 | 0.06 | 2.11% | 2.85 | 2.96 | 2.85 |
| Apr 15, 2024 | 2.93 | 0.05 | 1.74% | 2.88 | 3.05 | 2.84 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Heron Therapeutics, Inc. Company profile
About Heron Therapeutics Inc
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF (HTX-011), HTX-019, and HTX-034. HTX-011 is a dual-acting local anaesthetic that delivers a fixed-dose combination of the local anaesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. HTX-019 is an investigational agent for the prevention of postoperative nausea and vomiting. HTX-034 is a product candidate for postoperative pain management.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Heron Therapeutics Inc revenues decreased 3% to $86.3M. Net loss decreased 3% to $220.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects "Research and development - Balancing va decrease of 39% to $66.4M (expense), Stock-based Compensation in SGA decrease of 24% to $11.8M (expense).
Equity composition
Common Stock $.01 Par, 02/10, 50M auth., 40,143,227 issd. Insiders own 6.70%. IPO: 8/87, 2M shares @ $7.00 by Allen & Co. 2/92, private placement of 1,150,000 units (1 Share + 1 Warrant). 5/01, Name changed from Advanced Polymer Systems, Inc. FY'01 fncls. are restated. 05/07, 1-for-4 reverse stock split. 01/14, 1-for-20 Reverse stock split.
| Industry: | Biotechnology & Medical Research (NEC) |
4242 Campus Point Court, Suite 200
SAN DIEGO
CALIFORNIA 92121
US
News
Stock market crash: how far can the S&P 500 go?
After a remarkably strong first quarter, the US stock market pulled back in April for the first time since October last year.
11:46, 10 May 2024
Bank of England preview: possible rate cut in summer?
The Bank of England (BoE) is widely expected to keep interest rates unchanged when it meets later this week. Data from Reuters shows a 90% chance of no change to the current rate of 5.25%, but the central bank will need to decide whether to change the messaging about rate cuts this year as traders will be paying close attention to any rate-cut clues.
12:39, 8 May 2024
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com